These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31924504)

  • 61. Synthesis and biological evaluation of Santacruzamate-A based analogues.
    Randino R; Gazzerro P; Mazitschek R; Rodriquez M
    Bioorg Med Chem; 2017 Dec; 25(24):6486-6491. PubMed ID: 29100734
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
    Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
    [TBL] [Abstract][Full Text] [Related]  

  • 63.
    Pérez-Salvia M; Aldaba E; Vara Y; Fabre M; Ferrer C; Masdeu C; Zubia A; Sebastian ES; Otaegui D; Llinàs-Arias P; Rosselló-Tortella M; Berdasco M; Moutinho C; Setien F; Villanueva A; González-Barca E; Muncunill J; Navarro JT; Piris MA; Cossio FP; Esteller M
    Haematologica; 2018 Nov; 103(11):e537-e540. PubMed ID: 29880608
    [No Abstract]   [Full Text] [Related]  

  • 64. Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
    Guo Z; Zhang Z; Zhang Y; Wang G; Huang Z; Zhang Q; Li J
    Eur J Med Chem; 2021 Jun; 218():113383. PubMed ID: 33799069
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
    Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
    J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
    Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
    Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
    Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
    ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design, synthesis and biological evaluation of selective histone deacetylase 6 (HDAC6) inhibitors bearing benzoindazole or pyrazoloindazole scaffold as surface recognition motif.
    Xu Q; Mou Y; Wang S; Gao X; Zhang Y; Wang Z; Xu X; Han Y; Jia W; Zhang M; Zhao L; Liu D
    Bioorg Chem; 2021 Jun; 111():104910. PubMed ID: 33894432
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
    Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
    Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
    Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
    J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
    Lee HY; Chang CY; Su CJ; Huang HL; Mehndiratta S; Chao YH; Hsu CM; Kumar S; Sung TY; Huang YZ; Li YH; Yang CR; Liou JP
    Eur J Med Chem; 2016 Oct; 122():92-101. PubMed ID: 27344487
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
    Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
    Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
    Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
    Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
    Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC.
    Bao X; Sun Y; Bao C; Zhang J; Zou S; Yang J; Wu C; Wang L; Chen G
    Bioorg Chem; 2019 May; 86():696-704. PubMed ID: 30831531
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
    Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
    Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
    Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.